New hope for tough breast cancer: drug combo trial launches

NCT ID NCT07376629

ENROLLING_BY_INVITATION Disease control Sponsor: Huabo Biopharm Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called HB0025 combined with chemotherapy (nab-paclitaxel) as a first treatment for people with advanced triple-negative breast cancer that cannot be removed by surgery. The goal is to see if the combination is safe and works better than chemotherapy alone. About 60 adults who have not had prior treatment for metastatic disease will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TNBC

Contacts and locations

Locations

Affiliated Hospital of Jining Medical University

Jining, China
Anhui Provincial Hospital

Hefei, China
Anyang Cancer Hospital

Anyang, China
Fudan University Shanghai Cancer Center

Shanghai, China
Fujian Cancer Hospital

Fujian, China
Guangdong Provincial People's Hospital

Guangdong, China
Harbin Medical University Cancer Hospital

Harbin, China
Jiangsu Province Hospital

Nanjing, China
Liaoning Cancer Hospital

Shengyang, China
Linyi Cancer Hospital

Linyi, China
Shandong Cancer Hospital

Shandong, China
Shanxi Cancer Hospital

Shanxi, China
Sichuan Cancer Hospital

Chengdu, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

Hangzhou, China
Sun Yat-sen University Cancer Center

Guangzhou, China
The First Affiliated Hospital of Xiamen University

Xiamen, China
The First Hospital of Jilin University

Jilin City, China
The Second Affiliated Hospital of Soochow University

Suzhou, China
The Second Affiliated Hospital of Xi'an Jiaotong University

Xi'an, China
Tianjin Cancer Hospital

Tianjing, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, China
Xiangya Hospital Central South University

Changsha, China
Xuzhou Central Hospital

Xuzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.